Q: What is Ukoniq used for?

Ukoniq is used to treat relapsed or refractory marginal zone lymphoma and follicular lymphoma (FDA approval withdrawn).

Q: What are the active ingredients in Ukoniq?

The active ingredient in Ukoniq is Umbralisib .

Q: What are the side effects of Ukoniq?

Common side effects of Ukoniq may include: Nausea and indigestion Diarrhea Feeling tired or weak (fatigue) Muscle or joint pain Upper respiratory tract infections Skin rash Low levels of red blood cells, white blood cells, or platelets Some side effects can be severe and require immediate medical attention. Serious risks associated with Ukoniq include: Severe diarrhea or colitis: Inflammation of the colon that can lead to serious complications. Liver toxicity: Changes in liver function tests or liver damage. Infections: An increased risk of developing serious infections, such as pneumonia. Severe skin reactions: Rashes that may be painful or cover large areas of the body. Increased risk of death: Clinical trial findings indicated a higher risk of death in patients treated with Ukoniq compared to those receiving other treatments, which led to the drug's withdrawal from the market. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ukoniq?

Ukoniq belongs to the PI3K delta and CK1 epsilon inhibitor drug class.

Q: What is the dosage of Ukoniq and how do I take it?

General Instructions Ukoniq was provided as a tablet to be taken by mouth once daily. It was important to take the medication at approximately the same time each day and to always take it with a meal. Tablets were meant to be swallowed whole; they should not be chewed, crushed, or broken. Missed Dose If a dose was missed, it could be taken later that same day. However, if the missed dose was not remembered until the following day, it was skipped, and the regular dosing schedule was resumed. Two doses should not be taken at once to make up for a missed dose. Important Safety Update The Food and Drug Administration (FDA) has withdrawn the approval for Ukoniq, and the manufacturer has removed it from the market. This action was taken because clinical trial data suggested an increased risk of death for patients taking the drug. Patients currently using this medication should contact their healthcare provider to discuss alternative treatment options.

Q: Is Ukoniq safe during pregnancy and breastfeeding?

Pregnancy Based on findings from animal studies, Ukoniq can cause fetal harm when administered to a pregnant woman. There are no available data on the use of this medication in pregnant humans to inform a drug-associated risk of major birth defects or miscarriage. Healthcare providers typically recommend the following for individuals of reproductive potential: Pregnancy Testing: Females who can become pregnant should have a pregnancy test to confirm they are not pregnant before starting treatment. Contraception for Females: Females of reproductive potential should use effective contraception during treatment and for at least one month after the final dose. Contraception for Males: Males with female partners of reproductive potential should use effective contraception during treatment and for at least one month after the final dose. If you become pregnant or think you may be pregnant while taking this medication, contact your healthcare provider immediately. Breastfeeding It is not known whether Ukoniq passes into human breast milk or if it affects milk production. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least one month after the last dose. Patients should discuss the risks and benefits of treatment with their healthcare team to make an informed decision regarding pregnancy and breastfeeding, especially given that the FDA has withdrawn approval for this medication due to safety concerns.

Q: What forms and strengths does Ukoniq come in?

Ukoniq was supplied in the following form: Oral tablet This medication is no longer available. The manufacturer voluntarily withdrew Ukoniq from the market, and the FDA withdrew its approval because of data showing a possible increased risk of death in patients taking the drug.

Q: What is the FDA approval status of Ukoniq?

FDA Withdrawal In June 2022, the U.S. Food and Drug Administration (FDA) officially withdrew its approval for Ukoniq. This action followed a voluntary request from the manufacturer to withdraw the drug from the market after clinical trial data raised significant safety concerns. Reason for Withdrawal The withdrawal was based on findings from the UNITY-CLL clinical trial, which evaluated Ukoniq in patients with chronic lymphocytic leukemia. The trial data showed a possible increased risk of death in patients receiving Ukoniq compared to those in the control group. The FDA determined that the risks of the medication outweighed its benefits for its approved uses. Former Indications Before its removal from the market, Ukoniq had received accelerated approval to treat adults with: Relapsed or refractory marginal zone lymphoma (MZL) Relapsed or refractory follicular lymphoma (FL) Because the drug is no longer approved, it is no longer indicated for these conditions. Healthcare providers were advised to stop prescribing the medication and to transition patients to alternative treatment options. Regulatory History Ukoniq was initially granted accelerated approval in February 2021. However, by early 2022, the FDA issued safety communications investigating the increased risk of death and other serious side effects. This investigation eventually led to the voluntary market withdrawal and the formal revocation of FDA approval.

Question 1

What is Ukoniq?

Accepted Answer

Ukoniq works by blocking the action of specific proteins that signal cancer cells to multiply and survive. By targeting these proteins, the medication helps to disrupt the life cycle of the cancer cells and slow the progression of the disease.

Question 2

What is Ukoniq used for?

Accepted Answer

Ukoniq is used to treat relapsed or refractory marginal zone lymphoma and follicular lymphoma (FDA approval withdrawn).

Question 3

How does Ukoniq work?

Accepted Answer

Ukoniq works by blocking the activity of specific proteins that help cancer cells grow and multiply. It is classified as a kinase inhibitor, which is a type of drug that interferes with the signaling pathways inside cells.

The medication primarily targets two proteins:

PI3K-delta: This protein is found in B-cells, a type of white blood cell. In certain lymphomas, this protein is overactive, sending signals that allow cancer cells to survive and spread.
CK1-epsilon: This protein is involved in regulating cell growth and development.

By inhibiting these proteins, Ukoniq disrupts the life cycle of the cancer cells, making it harder for them to survive and potentially leading to a reduction in tumor size.

Question 4

What are the active ingredients in Ukoniq?

Accepted Answer

The active ingredient in Ukoniq is Umbralisib.

Question 5

What are the side effects of Ukoniq?

Accepted Answer

Common side effects of Ukoniq may include:

Nausea and indigestion
Diarrhea
Feeling tired or weak (fatigue)
Muscle or joint pain
Upper respiratory tract infections
Skin rash
Low levels of red blood cells, white blood cells, or platelets

Some side effects can be severe and require immediate medical attention. Serious risks associated with Ukoniq include:

Severe diarrhea or colitis: Inflammation of the colon that can lead to serious complications.
Liver toxicity: Changes in liver function tests or liver damage.
Infections: An increased risk of developing serious infections, such as pneumonia.
Severe skin reactions: Rashes that may be painful or cover large areas of the body.
Increased risk of death: Clinical trial findings indicated a higher risk of death in patients treated with Ukoniq compared to those receiving other treatments, which led to the drug's withdrawal from the market.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ukoniq?

Accepted Answer

Ukoniq belongs to the PI3K delta and CK1 epsilon inhibitor drug class.

Question 7

What is the dosage of Ukoniq and how do I take it?

Accepted Answer

General Instructions

Ukoniq was provided as a tablet to be taken by mouth once daily. It was important to take the medication at approximately the same time each day and to always take it with a meal. Tablets were meant to be swallowed whole; they should not be chewed, crushed, or broken.

Missed Dose

If a dose was missed, it could be taken later that same day. However, if the missed dose was not remembered until the following day, it was skipped, and the regular dosing schedule was resumed. Two doses should not be taken at once to make up for a missed dose.

Important Safety Update

The Food and Drug Administration (FDA) has withdrawn the approval for Ukoniq, and the manufacturer has removed it from the market. This action was taken because clinical trial data suggested an increased risk of death for patients taking the drug. Patients currently using this medication should contact their healthcare provider to discuss alternative treatment options.

Question 8

Is Ukoniq safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Based on findings from animal studies, Ukoniq can cause fetal harm when administered to a pregnant woman. There are no available data on the use of this medication in pregnant humans to inform a drug-associated risk of major birth defects or miscarriage.

Healthcare providers typically recommend the following for individuals of reproductive potential:

Pregnancy Testing: Females who can become pregnant should have a pregnancy test to confirm they are not pregnant before starting treatment.
Contraception for Females: Females of reproductive potential should use effective contraception during treatment and for at least one month after the final dose.
Contraception for Males: Males with female partners of reproductive potential should use effective contraception during treatment and for at least one month after the final dose.

If you become pregnant or think you may be pregnant while taking this medication, contact your healthcare provider immediately.

Breastfeeding

It is not known whether Ukoniq passes into human breast milk or if it affects milk production. Because of the potential for serious side effects in a breastfed child, it is generally advised not to breastfeed during treatment and for at least one month after the last dose.

Patients should discuss the risks and benefits of treatment with their healthcare team to make an informed decision regarding pregnancy and breastfeeding, especially given that the FDA has withdrawn approval for this medication due to safety concerns.

Question 9

What forms and strengths does Ukoniq come in?

Accepted Answer

Ukoniq was supplied in the following form:

Oral tablet

This medication is no longer available. The manufacturer voluntarily withdrew Ukoniq from the market, and the FDA withdrew its approval because of data showing a possible increased risk of death in patients taking the drug.

Question 10

What is the FDA approval status of Ukoniq?

Accepted Answer

FDA Withdrawal

In June 2022, the U.S. Food and Drug Administration (FDA) officially withdrew its approval for Ukoniq. This action followed a voluntary request from the manufacturer to withdraw the drug from the market after clinical trial data raised significant safety concerns.

Reason for Withdrawal

The withdrawal was based on findings from the UNITY-CLL clinical trial, which evaluated Ukoniq in patients with chronic lymphocytic leukemia. The trial data showed a possible increased risk of death in patients receiving Ukoniq compared to those in the control group. The FDA determined that the risks of the medication outweighed its benefits for its approved uses.

Former Indications

Before its removal from the market, Ukoniq had received accelerated approval to treat adults with:

Relapsed or refractory marginal zone lymphoma (MZL)
Relapsed or refractory follicular lymphoma (FL)

Because the drug is no longer approved, it is no longer indicated for these conditions. Healthcare providers were advised to stop prescribing the medication and to transition patients to alternative treatment options.

Regulatory History

Ukoniq was initially granted accelerated approval in February 2021. However, by early 2022, the FDA issued safety communications investigating the increased risk of death and other serious side effects. This investigation eventually led to the voluntary market withdrawal and the formal revocation of FDA approval.

Question 11

What should I know about Ukoniq and cost?

Accepted Answer

Market Withdrawal and Availability

As of 2022, Ukoniq (umbralisib) is no longer marketed or sold in the United States. The U.S. Food and Drug Administration (FDA) withdrew its approval for the medication after clinical trial data suggested an increased risk of death in patients taking the drug. Consequently, the manufacturer voluntarily withdrew Ukoniq from the market.

Cost and Insurance Information

Because Ukoniq has been removed from the market, there is no current pricing information, and it is no longer covered by insurance providers. Financial assistance programs and co-pay cards that may have existed previously are no longer active. Patients should not attempt to purchase this medication from any source.

Next Steps for Patients

If you were previously prescribed Ukoniq, you should contact your healthcare provider to discuss alternative treatment options. Your medical team can provide information on the costs and coverage for other approved therapies that may be appropriate for your condition.

Ukoniq

📋Overview

How It Works

Uses

Active Ingredients

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Ukoniq

Hospitals.net Disclosure